SOLIGENIX, INC.

Soligenix, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing products for rare diseases with unmet medical needs. The company's headquarters are situated in Princeton, New Jersey, United States.

The company operates through two primary business segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment focuses on developing treatments for orphan diseases, including HyBryte™ (SGX301) for cutaneous T-cell lymphoma (CTCL), SGX302 for psoriasis, and dusquetide (SGX942/SGX945) for oral mucositis and Behçet's Disease. The Public Health Solutions segment is involved in developing vaccines and therapeutics for biodefense and infectious diseases, such as RiVax® (a ricin toxin vaccine), and programs targeting filoviruses (e.g., Ebola, Marburg) and coronaviruses (CiVax™ for COVID-19), leveraging its proprietary ThermoVax® heat stabilization platform technology.

Christopher J. Schaber, PhD, leads the company as its Chairman, President, and Chief Executive Officer. In April 2026, the interim efficacy analysis of its pivotal Phase 3 FLASH2 trial for HyBryte™ in CTCL was recommended to halt for futility. Despite this, Soligenix continues to advance other pipeline assets, such as dusquetide for Behçet's Disease, which has received Orphan Drug Designation from the European Commission and Promising Innovative Medicine designation in the UK. The company is actively evaluating strategic options, including partnerships, mergers, acquisitions, and financing opportunities, to further advance its late-stage pipeline.